Rosenbloom: No More Exploitation of Seniors, Taxpayers by PBMs
Published by Health Economics
Pharmacy benefit managers have long enough taken advantage seniors and taxpayers in the U.S. through strategies that exploit Medicare, Senior Care Pharmacy Coalition President/CEO Alan Rosenbloom writes in a recent article published on McKnight’s.
High costs under Medicare Part D, Rosenbloom writes, has facilitated an “anti-competitive oligopoly,” filling the pockets of conglomerates whose tendrils span across inter-related markets, including private insurers, pharmacy benefit managers and pharma chains.
“In fact, only three such conglomerates dominate the PBM market and chain pharmacies in the retail, mail order, specialty and LTC pharmacy markets, while increasingly controlling predominant Part D Plans,” Rosenbloom writes.
According to Rosenbloom, three PBMs connected to the conglomerates process some 90 percent of the prescriptions for LTC pharmacies.
“This market concentration … is stifling competition and driving up health care costs for seniors and taxpayers alike,” he writes.
Click here to see the original article on the Health Economics website.
Recent Posts
-
Senior Care Pharmacy Coalition Opposes CMS Final Rule on Minimum Staffing Standards for LTC Facilities
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy sector, released a statement today regarding its opposition to the Centers for Medicare & Medicaid Services (CMS) final rule on minimum staffing standards for long-term care (LTC) facilities.
-
Senior Care Pharmacy Coalition Shares Comments with CMS Regarding Medicare Part D Restructuring Guidance: “Smoothing Provisions”
SCPC filed comments with CMS in response to their guidance on the implementation of the Medicare Part D restructuring portion of the Inflation Reduction Act (IRA).
-
Drug pricing efforts threaten ‘very existence’ of LTC pharmacies: reps
President Biden in his State of the Union address last week vowed to end “Big Pharma’s” grip on prescription drug pricing and cut costs for seniors and taxpayers by another $200 million.
But the president’s plans to expand his administration’s first-ever Medicare drug price negotiations could spell big trouble for the pharmacists who support seniors living in long-term care settings, advocates warned in response.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.